SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-105097
Filing Date
2023-04-18
Accepted
2023-04-18 16:58:51
Documents
13
Period of Report
2023-04-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d478702d8k.htm   iXBRL 8-K 24288
5 GRAPHIC g478702g0417080350969.jpg GRAPHIC 4144
  Complete submission text file 0001193125-23-105097.txt   158279

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA evlo-20230414.xsd EX-101.SCH 2842
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE evlo-20230414_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evlo-20230414_pre.xml EX-101.PRE 11253
7 EXTRACTED XBRL INSTANCE DOCUMENT d478702d8k_htm.xml XML 3345
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 23827536
SIC: 2834 Pharmaceutical Preparations